Niklason Laura E 4

What Happened

• Laura E. Niklason, President, CEO and Director of Humacyte, was granted a derivative award for 80,000 shares on June 11, 2026. The filing reports the acquisition amount as $0.00 (no cash paid at grant). This is a grant of an equity award (option-style) rather than a purchase or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-12 (timely filing).
• Transaction type/code: A = Award/Grant (derivative).
• Shares/units granted: 80,000.
• Reported price at acquisition: $0.00 (common for option or RSU grants; does not imply market value).
• Vesting footnote: First 25% vests on June 11, 2027; thereafter 1/48 of the option vests monthly on the 11th through June 11, 2030.
• Shares owned after transaction: Not specified in the provided filing details.
• No indication of immediate sale or cashless exercise in this filing.

Context

• This is a compensation-related option/award grant that vests over time; it does not represent an immediate purchase or sale of stock. Such grants are commonly used for retention and long-term incentive purposes and do not by themselves signal near-term insider buying or selling.